ContributorsPublishersAdvertisers

#Flagship Pioneering

biopharmadive.com

Top Merck executive to depart company for CEO role at ingredients maker

Frank Clyburn, a top Merck & Co. executive who oversees large portions of the drugmaker's business, will depart next month to take up a CEO job at IFF, a large New York-based manufacturer of ingredients in the food, fragrance and health industries. Clyburn's last day at Merck will be Feb....
BUSINESS
Picture for Top Merck executive to depart company for CEO role at ingredients maker
TRENDING TOPICS
geneticliteracyproject.org

CRISPR’s biggest challenge is addressing complex hereditary ailments like cystic fibrosis — but progress is being made

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation. It is posted under Fair Use guidelines. Treatments based on the Nobel-prize winning Crispr gene-editing approach can make permanent changes to a genetic flaw— but those edits...
MEDICAL & BIOTECH
neo.life

What to expect in neuroscience, genetics, longevity, biotech, and psychedelics in 2022

We ask the experts what’s coming in the next 12 months. Since 2022 started out with one of the biggest headlines of recent years—that a surgical team transplanted a genetically engineered pig heart into a living person—we can be forgiven, perhaps, for expecting that there will be many more astonishing things to happen on the neobiological frontier in the coming 12 months. So what will they be? We turned to some of the visionaries and innovators who normally help us see deeply into the future and asked them to make some predictions about the next 11 months.
MEDICAL & BIOTECH
cancerletter.com

Rémy Evard named chief digital officer and head of technology at MSK

Rémy Evard has joined Memorial Sloan Kettering Cancer Center as chief digital officer and head of technology. He succeeds Claus Jensen, who left MSK in May 2021. Evard previously worked for Flagship Pioneering, where he served as chief information and digital officer since 2018. Prior to that, Evard was global chief information officer at the Novartis Institutes of BioMedical Research from 2006 to 2018 and held various technical leadership roles at Argonne National Laboratory from 1996 to 2006, including chief information officer.
BUSINESS
beckershospitalreview.com

Memorial Sloan Kettering names chief digital officer

Rémy Evard has joined New York City-based Memorial Sloan Kettering Cancer Center as chief digital officer and head of technology. He succeeds Claus Jensen, who left the organization in May 2021, a news release said. "[Mr. Evard] joins MSK at a critical moment in our history as several developments...
NEW YORK CITY, NY
biospace.com

Flagship’s Afayan Outlines Biotech’s Top 4 Trends

Today, Noubar Afayan, founder of Flagship Pioneering, published the venture capital firm’s 2022 Annual Letter, and in it, outlined what he sees as the four top forces shaping the future of biotech. Earlier this week, a Flagship-backed company, Generate Bio, inked an almost $2 billion deal for protein therapeutics...
MEDICAL & BIOTECH
justicenewsflash.com

Memorial Sloan Kettering Appoints Rémy Evard as Chief Digital Officer

The New York City-based nonprofit said Thursday that Rémy Evard, a former head of technology at the life sciences venture capital firm, has joined Memorial Sloan Kettering Cancer Center as chief digital officer and head of technology. Ewald succeeds Klaus Janssen, Who left Memorial Sloan Caitlin In May, served...
NEW YORK CITY, NY
Phramalive.com

Amgen Strikes Nearly $2 Billion Deal for Protein Therapeutics

Amgen and Generate Biomedicines inked a research partnership to discover and develop protein therapeutics for five clinical targets. Generate Bio is focused on leveraging machine learning and artificial intelligence (AI) to program novel protein therapies around generative biology. Under the terms of the collaboration, Amgen is paying Generate $50 million...
MEDICAL & BIOTECH
bioworld.com

$1.9B-plus deal pairs Generate with Amgen in protein therapeutics

Less than two months after banking a hefty series B financing, Generate Biomedicines Inc. has scored a deal with Amgen Inc. that brings $50 million up front in an arrangement that could be worth $1.9 billion, as well as royalties on any resulting products. The pair will discover and create...
CAMBRIDGE, MA
YOU MAY ALSO LIKE